Medical Necessity Assessment for Rheumatoid Arthritis Treatment

Evidence Requirements for Biologic Continuation

The European League Against Rheumatism (EULAR) recommends monitoring every 1-3 months in active disease, with therapy adjustment if no improvement occurs by 3 months after treatment initiation 1
Clinical response should be documented using objective measures including tender/swollen joint counts, pain scales, functional assessments, and inflammatory markers (CRP, ESR) 2, 3
The American College of Rheumatology emphasizes that treatment decisions should be based on documented disease activity and response to prior therapies 4, 3

Objective disease activity measures are missing - no documented tender/swollen joint counts, no disease activity scores (DAS28, CDAI, or SDAI) 2, 4

MCG criteria state "concurrent treatment with methotrexate" is required but "NOT MET, STOPPED DUE TO TRANSAMINITIS" 1
The patient's methotrexate intolerance (transaminitis) is a legitimate contraindication, but this creates a coverage barrier under the stated authorization criteria 1

Historical clinical records showing objective improvement during prior infliximab therapy, including baseline and follow-up tender/swollen joint counts, disease activity scores (DAS28, CDAI, or SDAI), patient-reported outcomes (HAQ-DI, pain scales), and inflammatory markers (CRP, ESR) demonstrating improvement 2, 4, 3
Current disease activity assessment documenting active rheumatoid arthritis requiring escalation, including current tender/swollen joint counts, current disease activity score indicating moderate to high disease activity, and documentation that rituximab has been given adequate trial duration (typically 6 months minimum) 2, 1, 3

Trial of a different TNF inhibitor not previously used (certolizumab pegol or golimumab), as these may be effective even after adalimumab failure 1
Switch to non-TNF biologic with different mechanism such as tocilizumab (IL-6 inhibitor) or JAK inhibitors (tofacitinib, baricitinib, upadacitinib), which are appropriate after multiple DMARD failures 4, 1, 3

Multiple guidelines support biosimilar infliximab use as equivalent to originator infliximab for both treatment-naïve patients and those switching from originator 5, 6
The NOR-SWITCH study demonstrated non-inferiority of biosimilar infliximab (CT-P13) versus originator across multiple conditions including rheumatoid arthritis 5, 6

Do not approve based solely on patient recollection of prior benefit without objective clinical documentation 2, 4
Do not assume all TNF inhibitors are interchangeable - while class effect exists, individual patient responses vary and prior response to one TNF inhibitor should be documented before restarting that specific agent 1
Do not overlook alternative treatment options that may be more appropriate given the patient's complex treatment history and inability to use methotrexate 4, 1, 3

The European League Against Rheumatism (EULAR) 2020 guidelines recommend that once the desired treatment target is reached, it should be maintained throughout the remaining course of the disease, which supports the continuation of Remicade 10mg/kg IV every 6 weeks in patients with rheumatoid arthritis who have demonstrated clinical response 7
The treat-to-target approach emphasizes that therapy should be adjusted every 3 months until the desired target is reached, then maintained, which is relevant for patients with rheumatoid arthritis on Remicade therapy 8
Patients who achieve clinical response should continue their effective regimen rather than switching to unproven alternatives, as recommended by EULAR 2020 guidelines 7

Disease activity should be assessed every 3-6 months in patients maintaining low disease activity or remission, including validated composite measures (DAS28, CDAI, or SDAI) with joint counts, as recommended by EULAR guidelines 7 8

EULAR guidelines recognize that methotrexate intolerance is a legitimate contraindication, and infliximab monotherapy remains appropriate for patients with rheumatoid arthritis 7

If cost is a concern, switching to biosimilar infliximab (CT-P13) is supported by evidence showing non-inferiority to originator infliximab, and the dose and frequency should remain unchanged at 10mg/kg every 6 weeks 9